NeuroBANK™ and Global Unique Patient Identifier Allow for Secure Collaboration, Data Aggregation and Sharing (S46.007)
Citation Manager Formats
Make Comment
See Comments

Abstract
OBJECTIVE: Introduce standardized yet flexible approach to secure collaboration, integration, harmonization and sharing of clinical and research information. BACKGROUND: It is beneficial for medical and research community to aggregate and cross-link clinical and research information from clinical visits, clinical studies, health records, and self-reported patient outcomes, and to connect it to biospecimen and image repositories. Data duplication shall be avoided. Regulations prevent sharing protected health information (PHI). DESIGN/METHODS: The NIH-developed Global Unique ID (GUID) technology allows linking various data sources into coherent distributed meta-dataset, while maintaining regulatory compliance. A disease-area-specific central authority for generating GUIDs is set up by Neurological Clinical Research Institute to assist the neurodegenerative diseases clinical and research community with collecting patients’ data and linking it to other information. Advantages of GUID utilization are: • PHI does not leave the client computer; • Random-number-generated ID is not PHI-derived; • Centrally-generated GUIDs may be utilized in multiple applications and on various platforms; • Independently created datasets can be linked together; • A pseudo-GUID may be replaced with a real GUID when patient information becomes available, which is advantageous for legacy datasets integration; • GUIDs are unique yet untraceable back to the patient. RESULTS: NeuroBANK™ platform allows aggregation of existing datasets and direct data capture. Integration of the GUID technology with NeuroBANK™ provides mechanism of linking same-patients’ data from multiple sources. The GUID utilization is recommended for cross-linking data to biospecimen and image repositories. CONCLUSIONS: GUID technology is uniquely suitable for use with de-identified datasets. It may link biospecimen collections and images with clinical and research data and electronic health records. Clinicians and researchers are encouraged to us GUID platform, which will also facilitate international scientific collaboration. GUIDs may be utilized by international researchers and clinicians with or without their current affiliation with NeuroBANK™ and other collaboration efforts. Study Supported by: ALS Association
Disclosure: Dr. Sherman has nothing to disclose. Dr. Katsovskiy has nothing to disclose. Dr. Selsov has nothing to disclose. Dr. Sinani has nothing to disclose. Dr. Walker has nothing to disclose. Dr. Berry has received personal compensation for activities with Oakstone Publishing, the Muscular Dystrophy Association, and ALS Therapy Alliance. Dr. Katz has received personal compensation for activities with Blue Cross and Griffols. Dr. Katz has received research support from Cytokinetics. Dr. Cudkowicz has received personal compensation for activities with Trophos, GlaxoSmithKline Inc., Biogen Idec, and Teva Neuroscience. Dr. Cudkowicz has received research support from Biogen Idec, and Neuraltis.
Thursday, May 1 2014, 1:00 pm-2:45 pm
- Copyright © 2014 by AAN Enterprises, Inc.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.